IPH 4201 enters in pre-clinical validation
Innate Pharma SA announces the entry in pre-clinical validation of a new drug candidate: IPH 4201. IPH 4201 is a monoclonal antibody targeting a specific antigen on pancreatic cancer cells.
Programs & products
Vivalis and Innate Pharma sign a collaboration and commercial license agreement
Vivalis and Innate Pharma sign a collaboration and commercial license agreement to develop Innate's novel monoclonal antibody, to be manufactured with Vivalis' EB66® platform, for rare cutaneous...
Milestone payment in IPH 24 project developed in collaboration with Novo Nordisk A/S
Innate Pharma SA announces the achievement of a milestone payment in a new monoclonal antibody project developed in collaboration with Novo Nordisk A/S.